Advisornet Financial’s Lantern Pharma LTRN Stock Holding History

Advisornet Financial’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-500	Closed	-$6K	–	2100
2021 Q3	$6K	Buy	+500	New	+$6.47K	﹤0.01%	1584

Other funds holding LTRN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Advisornet Financial's LTRN Position: Q4 2021 in Review

Advisornet Financial sold out of Lantern Pharma (LTRN) in Q4 2021, closing a stake of 500 shares — an estimated $6K sold.

Advisornet Financial first reported a position in LTRN in Q3 2021 and held it in 1 quarter. The position peaked at $6K in Q3 2021. 33 funds tracked by Wall St. Rank hold LTRN as of Q4 2021.

Advisornet Financial reported no remaining Lantern Pharma position as of Q4 2021 after selling out during the quarter.
Advisornet Financial sold 500 Lantern Pharma shares in Q4 2021, an estimated $6K.
Advisornet Financial first reported a position in Lantern Pharma in Q3 2021 and held it in 1 quarter.
Advisornet Financial's Lantern Pharma position peaked at $6K in Q3 2021.
33 funds tracked by Wall St. Rank held Lantern Pharma as of Q4 2021.

Based on Advisornet Financial's 13F filing for Q4 2021, filed 19 Jan 2022.